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SSRIs have been shown to be an 
effective treatment for 
moderate/severe depression. 
However in 2004 they were 
given a “black box” warning 
indicating the potential 
relationship between the drug 
and increased risk of suicidal 
behavior or ideation.
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In 2018, suicide was found to be the 
second leading cause of death for 
people aged 10 - 34 in the United 
States. 
At least 90% of suicides are found 
to be comorbid with mental 
illness, most commonly: 
depression 
The monoamine hypothesis is the 
current leading hypothesis to 
explain depression on a 
biochemical basis. Accordingly, 
SSRIs are the most commonly 
prescribed antidepressant
This thesis aims to investigate the costs and benefits of prescribing 
SSRIs to treat depression. I will be elucidating the mechanism of 
SSRIs and their highly contested relationship with suicide risk. 
The Monoamine Hypothesis of Depression
• Proposes depression is caused by a decrease of serotonergic and 
noradrenergic transmission between neurons
• Hence, this theory proposes SSRIs treat depression by increasing 
the concentration of these neurotransmitters in the synapses 
The BDNF Hypothesis of Depression 
• Proposes that depression is related to reduced Brain Derived 
Neurotrophic Factor (BDNF) levels in the hippocampus 
• SSRIs promote BDNF activity along with several other forms of 
neuroplasticity
• Suicidal people have been shown to have severe decline in 
neuroplasticity
Flowcharts courtesy of Dr. Jena Hales
Just, et al. Machine learning of neural representations  suicide and 
emotion concepts identifies suicidal youth. 2017. Nature. 
The comorbidity of 
depression and suicidal 
ideation is generally 
accepted to be ubiquitous. 
However, many suicidal 
patients also suffer from 
other psychopathologies 
that complicate the 
relationship between the 
two. Recent research 
investigates the 
neurological underpinnings 
of both suicidal ideation 
and major depressive 
disorder (MDD) and has 
possibly developed a way
diagnose these disorders through brain scans. These diagnoses could 
lead to more accurate prescriptions of medications and a deeper 
understanding of exactly how SSRIs elicit their antidepressant 
symptoms, and possibly, an increased risk in suicidal behavior. The
above image depicts the differences in fMRI activation between suicidal
and non-suicidal patients. A machine-learning algorithm was 
successfully able to differentiate between these groups of patients; 
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Overall, the data indicates that caution should be used when 
prescribing SSRIs, but they are an effective and low-risk treatment
for depression. However, there are still many unanswered 
questions about these drugs:
• What is the reason for the different risks for suicidality seen in
adolescents and children compared to adults?
• What determines if a patient will experience increased suicidal 
risk after taking SSRIs?
• Do SSRIs lead to a decrease in suicidal ideation, attempts, or 
completion in patients if they do not lead to an increase?
• What is the exact mechanism through which SSRIs elicit their 
effects?
• How can physicians determine the safest, most effective 
method of treatment for their patients?
• How can physicians assess suicidal risk?
We can all help prevent suicide. For more information on resources visit suicidepreventionlifeline.org or call 
the National Suicide Prevention Lifeline at 1-800-273-8255
The relationship 
between suicidality and 
SSRIs has been highly 
contested since they 
were given the “black 
box” warning in 2004. 
Research on the topic is 
difficult to conduct 
considering the many 
variables that contribute
to suicide.
Ecological, observational, and randomized control 
studies have been conducted investigating the 
relationship between SSRIs and suicidality, but 
have several methodological limitations.  
The overall data suggests that there is a lack of 
evidence for the association between suicidality and 
SSRIs in adults and the elderly. However, children and 
adolescents may be at risk for increased suicidal 
ideations.  
Evidence suggests that clinicians should not be 
deterred from prescribing SSRIs to patients who 
may benefit. Nonetheless, there is a need for 
increased monitoring, and frequent risk 
assessment (especially in adolescents).
